April 2020: The Next Chapter
On the 24th of April, 2020, the latest set of results from PROfound were announced. Olaparib improves overall survival compared to the hormone therapies abiraterone and enzalutamide in men with advanced prostate cancer which has already spread throughout the body, who have stopped responding to hormone therapy, and who have changes in their DNA known as BRCA1/2 or ATM mutations. Mutations like these, which mean cancer cells struggle to fix faulty DNA, are thought to occur in approximately 20-30% of advanced, hormone therapy resistant prostate cancers. The companies who produce this drug are working with regulators to get it to patients as quickly as possible.
We at PCRC welcome this news, which is a fresh source of hope, and further proof that science is constantly moving forwards, towards a better future for anyone affected by prostate cancer.